On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Course objectives
- The promise of engineered models
- Why examine engineered mice?
- Production and validation of engineered models
- Types of engineered animals
- Transgenic mice by microinjection
- Knockout mice (gene targeting)
- Utilization of gene targeting technology
- Validation milestones for engineered models
- Characterization of genetically engineered animals
- Sample protocol for screening engineered animals
- Standardizing genetic and environmental variables
- Selecting the most appropriate engineered model
- Approaches to functional genomics
- Considerations for using engineered animals
- Engineered models in pharmaceutical research
- Pharmaceutical careers for engineered animals
- Screening for genetic toxicology
- Carcinogenicity testing with engineered mice
- Induced tumor rate in engineered models
- Industrial practice for carcinogenicity testing
- The Trp53 heterozygous mouse model
- The Tg.Ac mouse model
- rasH2 mouse model for short-term carcinogenicity
- Carcinogenicity assay - study design
- Carcinogenicity assay - hypothetical results
- Improvement in carcinogenicity testing
- Other mutant mouse models
- Mutagenicity testing with transgenic mice
- Abbreviations
- The molecular basis of the Big Blue mouse model
- Mutagenicity testing protocol
- The Big Blue mouse mutagenicity assay
- The Muta mouse mutagenicity assay
- In-vivo mutagenicity assay - study design
- Decision tree for carcinogenicity testing
- Engineered animals: assessing adverse outcomes
- Beta-secretase as a therapeutic target
- Impact of chronic beta-secretase blockade
- Artemin therapy for treating peripheral neuropathy
- Neural changes in adrenal after Artemin exposure
- Impact of Artemin supplementation
- Summary
- Further references
Topics Covered
- Engineered animals in drug development
- Why we use them
- How we generate them
- How we characterize them
- How we select which model to use
- How we use them
Links
Series:
Categories:
Talk Citation
Bolon, B. (2009, July 30). Non-clinical development of pharmaceuticals using engineered animal models [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/WEFV7181.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Brad Bolon has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Hide